Sacituzumab govitecan
Approved · FDARecent clinical, regulatory, research and industry developments relating to this drug.
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
Label change: SACITUZUMAB GOVITECAN (BLA761115)
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology3
- The New England journal of medicine2
- Annals of oncology : official journal of the European Society for Medical Oncology1
- Cancer discovery1
- Clinical pharmacokinetics1
- JCO oncology practice1
- Bardia A2
- Im SA2
- Kalinsky K2
- Mekan S2
- Schmid P2
- Tolaney SM2
- Wang X2
- Abdou Y1
- Massachusetts General Hospital2
- Seoul National University Hospital2
- Yale School of Medicine2
- AdventHealth Cancer Institute1
- Araujo Jorge Cancer Hospital1
- Asan Medical Center1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 10 of the same disease areas as Sacituzumab govitecan in the shared literature.
Studied across 10 of the same disease areas as Sacituzumab govitecan in the shared literature.
Studied across 7 of the same disease areas as Sacituzumab govitecan in the shared literature.
Studied across 5 of the same disease areas as Sacituzumab govitecan in the shared literature.
Studied across 5 of the same disease areas as Sacituzumab govitecan in the shared literature.
Studied across 3 of the same disease areas as Sacituzumab govitecan in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.